AN2 Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 12, 2025

ANTX$4.00+1.1%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Balance Sheets

(in thousands, except share and per share amounts)

	June 30,	December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$18,220	$21,351
Short-term investments	44,696	62,267
Prepaid expenses and other current assets	4,608	2,644
Total current assets	67,524	86,262
Long-term investments	8,301	5,021
Other assets, long-term	—	804
Total assets	$75,825	$92,087
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$2,113	$3,317
Accrued compensation	1,199	1,676
Accrued liabilities	2,954	4,454
Other current liabilities	717	791
Total liabilities	6,983	10,238
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.00001 par value; 10,000,000 shares authorized at June 30, 2025 and December 31, 2024; no shares issued and outstanding at June 30, 2025 and December 31, 2024	—	—
Common stock, $0.00001 par value; 500,000,000 shares authorized at June 30, 2025 and December 31, 2024; 27,376,461 and 29,919,634 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively	—	—
Additional paid-in capital	291,704	287,594
Accumulated other comprehensive gain	25	31
Accumulated deficit	(222,887)	(205,776)
Total stockholders’ equity	68,842	81,849
Total liabilities and stockholders’ equity	$75,825	$92,087

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.